Investigation of the "central vein sign" in infratentorial multiple sclerosis lesions.
Central vein sign
MRI
Multiple sclerosis
SWI
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
06
07
2020
revised:
14
07
2020
accepted:
16
07
2020
pubmed:
28
7
2020
medline:
15
5
2021
entrez:
26
7
2020
Statut:
ppublish
Résumé
Recently there has been an increasing interest in the "central vein sign" (CVS) in multiple sclerosis (MS) lesions. Infratentorial brain regions represent typical predilection sites for MS lesion development and are part of the current McDonald criteria to demonstrate dissemination in space, but only a few studies investigated the presence of the CVS in infratentorial MS lesions. The aim of this study was to investigate the CVS in infratentorial MS lesions. 3T MRI data sets from 119 patients with relapsing MS were analysed. Chronic lesions were identified on T2-weighted images. Co-registered T2 / susceptibility-weighted images (SWI) were analysed for the presence of the CVS. A total of 527 lesions were analysed. A CVS was present in the majority of infratentorial lesions (62/88, 70%). There was no difference in the frequencies of the CVS of infratentorial lesions compared to paraventricular lesions (67/81, 83%; p = 0.06) or subcortical (150/209; 72%; p = 0.82) lesions. Infratentorial lesions showed a CVS more often than juxtacortical lesions (16/34; 47%; p = 0.02), while periventricular lesions showed a CVS more often than infratentorial lesions (97/115; 84%, p = 0.02). CVS is a frequent finding in infratentorial MS lesions that may increase the diagnostic value in MS.
Sections du résumé
BACKGROUND
BACKGROUND
Recently there has been an increasing interest in the "central vein sign" (CVS) in multiple sclerosis (MS) lesions. Infratentorial brain regions represent typical predilection sites for MS lesion development and are part of the current McDonald criteria to demonstrate dissemination in space, but only a few studies investigated the presence of the CVS in infratentorial MS lesions. The aim of this study was to investigate the CVS in infratentorial MS lesions.
METHODS
METHODS
3T MRI data sets from 119 patients with relapsing MS were analysed. Chronic lesions were identified on T2-weighted images. Co-registered T2 / susceptibility-weighted images (SWI) were analysed for the presence of the CVS.
RESULTS
RESULTS
A total of 527 lesions were analysed. A CVS was present in the majority of infratentorial lesions (62/88, 70%). There was no difference in the frequencies of the CVS of infratentorial lesions compared to paraventricular lesions (67/81, 83%; p = 0.06) or subcortical (150/209; 72%; p = 0.82) lesions. Infratentorial lesions showed a CVS more often than juxtacortical lesions (16/34; 47%; p = 0.02), while periventricular lesions showed a CVS more often than infratentorial lesions (97/115; 84%, p = 0.02).
CONCLUSION
CONCLUSIONS
CVS is a frequent finding in infratentorial MS lesions that may increase the diagnostic value in MS.
Identifiants
pubmed: 32711298
pii: S2211-0348(20)30484-3
doi: 10.1016/j.msard.2020.102409
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102409Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr. Weber reports no disclosures. V. Sandicki reports no disclosures. Dr. Ebert reports no disclosures. Prof. Szabo reports no disclosures. Prof. Platten has a consultant relationship with Novartis, Merck, Genentech/Roche, has received non-personal, institutional honoraria from Medac, Merck, Novartis, TEVA, Genentech/Roche and has research agreements with Bayer Health Care. Prof. Gass has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis and TEVA Neurosciences. Dr. Eisele has received travel expenses from Bayer Health Care.